GALD.SW Galderma Group N
- Market cap
- CHF 45.0B
- P/E
- 66.5x
- P/B
- 6.50x
- ROE
- 21.1%
- Dividend yield
- 0.18%
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GALD.SW undervalued?
Graham numberThe Graham number of Galderma Group N cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galderma Group N fundamental analysis
9 of 22 checks passedROE 2/2
High return on equity (21.1%), above 20%.
ROA 1/1
Return on assets (12.8%) is above the industry median (3.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (153.3%) is above the industry median (24.7%).
Revenue Growth 2/2
Revenue grew 10.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (32.8%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 7.4x against interest expense, well covered.
PE vs Market 0/1
PE (66.5x) is above the market median (21.2x).
PE vs Industry 0/1
PE (66.5x) is above the industry median (19.0x).
PBV 0/1
Price to book (6.5x) is above the industry median (2.6x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 431.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.1%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 6.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Galderma Group N stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac…
Full company profileGalderma Group N financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galderma Group N annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.42B | 3.88B | 4.29B | 4.89B | 5.24B | 12.3B |
| Gross Profit | 2.38B | 2.65B | 2.99B | 3.40B | 3.61B | 8.41B |
| Operating Income | 329M | 354M | 536M | 710M | 829M | 2.45B |
| EBITDA | 524M | 633M | 851M | 1.03B | 1.21B | 3.09B |
| Net Income | -154M | -102M | -56.2M | 254M | 642M | 1.74B |
| EPS | -0.65 | -0.43 | -0.24 | 1.07 | 2.71 | 7.40 |
| Balance Sheet | ||||||
| Total Assets | 12.5B | 12.4B | 12.3B | 12.6B | 13.4B | 13.6B |
| Total Liabilities | 7.99B | 7.95B | 6.98B | 4.83B | 5.24B | 5.33B |
| Shareholders' Equity | 4.53B | 4.47B | 5.28B | 7.79B | 8.15B | 8.24B |
| Cash & Short-term Investments | 286M | 234M | 362M | 457M | 780M | 841M |
| Total Debt | 5.67B | 5.66B | 4.83B | 2.76B | 2.75B | 2.70B |
| Cash Flow | ||||||
| Operating Cash Flow | 196M | 115M | 165M | 430M | 1.19B | 2.24B |
| Capital Expenditure | 128M | 165M | 119M | 275M | 154M | 219M |
| Free Cash Flow | 67.7M | -49.8M | 43.3M | 213M | 1.03B | 2.02B |
| Ratios | ||||||
| ROE | -3.4% | -2.3% | -1.1% | 3.3% | 7.9% | 21.1% |
| ROA | -1.2% | -0.8% | -0.5% | 2.0% | 4.8% | 12.8% |
| Net Profit Margin | -4.5% | -2.6% | -1.3% | 5.2% | 12.3% | 14.2% |
| Debt to Equity | 1.25x | 1.27x | 0.91x | 0.35x | 0.34x | 0.33x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Galderma Group N dividends
- Dividend yield
- 0.18%
- Forward dividend
- 0.35 CHF
- Payout ratio
- 6.4%
- Ex-dividend date
- Apr 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 41.0M | 0.17 | 6.4% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Galderma Group N
- Insiders 21.00%
- Institutions 47.55%
- Public & others 31.45%
- Shares outstanding 233M
- Free float 131M
Galderma Group N company profile
- Company name
- Galderma Group N
- Ticker
- GALD.SW
- ISIN
- CH1335392721
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 7,676
- Fiscal year end
- December
- Address
- Zählerweg 10, Zug, Switzerland, 6300
- Phone
- 41 58 455 85 92
- Website
- galderma.com
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Galderma Group N management
5- Dr. Flemming Ornskov M.B.A., M.D., M.P.H.CEO & Director · born 1958
- Mr. Luigi Felice La CorteChief Financial Officer · born 1969
- Mr. Adrian MurphyHead of Global Operations · born 1970
- Mr. Emil IvanovHead of Strategy, Investor Relations & ESG
- Ms. Desislava Lazarova M.D.Global Head of Customer Education & Training